Blink Health, America’s leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health’s website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them.
To view the multimedia release go to:
https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
Allied Universal, a leading facility services company and the largest security force in North America, together with John Jay College and the Metropolitan Healthcare Security Directors Association (MHSDA), will host a “Plan to Live” seminar to educate healthcare providers on best practices to handle an active shooter situation and other threats. The free seminar will be held Tues., May 16, from 9 a.m. to 1:30 p.m. in the college’s Moot Court at 899 10th Avenue, New York City.
“Active shooters are not the only risks that healthcare facilities face,” said Kevin Francis, Business Development Specialist, Allied Universal. “Healthcare facilities may encounter aggressive assailants, bomb threats, and terrorist attacks. Our seminar provides tips and information from leading experts to help them prepare for, survive and recover from an attack.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7883351-allied-universal-john-jay-active-shooter-seminar/
Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Today, Johnson & Johnson, the world’s largest healthcare company, launches Johnson & Johnson Our Story at the Powerhouse and Johnson & Johnson Our Story to take visitors on a journey through time and around the world as they explore the stories behind more than 130 years of innovations that have changed the course of human health.
To view the multimedia release go to:
https://www.multivu.com/players/English/8077331-jnj-our-story/
Sandaire, an international family investment office with a base in Singapore and Delancey, a UK focused real estate advisory company, today launch Mount Kendal in Asia. Mount Kendal is a new collaboration between Delancey and Sandaire and will be focused on delivering bespoke UK real estate investment advice to Asian investors and international family offices.
Together, the two firms bring over 45 years of experience to Mount Kendal, which was established to deliver acquisition strategies and innovative asset management initiatives. Ultimately Mount Kendal seeks to create and protect value across a myriad of multi-sector, single asset or asset portfolio investments; from office, retail, residential and logistics; to healthcare, education, equity reversions and more.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8088051-sandaire-delancey-launch-mount-kendal/
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.
At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.
To view the multimedia release go to:
https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
St. Jude Children’s Research Hospital is naming the institution’s principal research tower after Donald Pinkel, M.D., whose legacy of driving progress toward advancing cures for pediatric catastrophic diseases continues at the institution today.
When St. Jude was established 55 years ago, Pinkel, the hospital’s first medical director, committed to finding cures for childhood cancer, leading to groundbreaking treatments that saved countless children’s lives. Many of these cancers were deemed incurable prior to Pinkel’s research, but his distinct approach to eradicating diseases established a model for how cancers could be treated.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924752-st-jude-childrens-research-hospital-donald-pinkel-tower/
Sanofi Consumer Healthcare – the makers of new Xyzal® Allergy 24HR, which is now available on retail shelves nationwide – revealed today the results of a social experiment in which 160 participants (80 allergy sufferers and 80 non-sufferers) wore a wearable device for 30 days to track their sleep and activity. The first-of-its-kind experiment found allergy symptoms can impact various elements of sufferers’ lives, including both the quality of their sleep and their daytime activities. Xyzal is partnering with renowned allergist Dr. Neeta Ogden to encourage allergy sufferers to Wise Up about the importance of managing their allergies this spring, so they can have a better night’s sleep and Rise Up in the morning to take on the day.
To view the multimedia release go to:
https://www.multivu.com/players/English/8029451-sanofi-xyzal-allergy-social-experiment-wise-up-rise-up/
GSK Consumer Healthcare and FLONASE® Sensimist™ Allergy Relief, along with Emmy® Award-winning choreographer and entertainer Derek Hough, today announced the launch of the 2017 Greater American Road Trip featuring social media’s favorite family, the Eh Bees. On Thursday, March 16, the Eh Bee family will begin their coast-to-coast journey to rethink allergy treatment and leave each city a little bit greater than they found it.
Derek, along with Eh Bee family members Mama Bee and her son Mr. Monkey, all suffer from allergies, but are determined to be greater than their itchy, watery eyesi and congested noses with the help of new FLONASE Sensimist. After kicking off the journey together in Los Angeles, Derek will challenge the Eh Bees and their allergies as they partner with local organizations throughout some of the worst allergy cities in the country.
To view the multimedia release go to:
https://www.multivu.com/players/English/8061451-flonase-greater-american-road-trip-derek-hough-eh-bee/
See America, Allergan’s initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to “stand in the way of darkness”.
The video harnesses Common’s striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss, and challenges us all to imagine a life without sight.
“I'm proud to join Allergan in the fight against preventable blindness,” said Common. “Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8057551-common-joins-allergan-see-america-against-preventable-blindness/
